Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nihon Ronen Igakkai Zasshi ; 60(1): 60-66, 2023.
Artigo em Japonês | MEDLINE | ID: mdl-36889724

RESUMO

A 75-year-old man visited our Collagen Disease Department because of a fever, edema in the lower legs, and arthralgia. He presented with peripheral arthritis of the extremities and was negative for rheumatoid factor, leading to a diagnosis of RS3PE syndrome. A search for malignancy was performed, but no obvious malignant findings were found. After starting treatment with steroid, methotrexate, and tacrolimus, the patient's joint symptoms improved, but after five months, enlarged lymph nodes throughout the body were observed. A lymph node biopsy revealed a diagnosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders/angioimmunoblastic T-cell lymphoma (OI-LPD/AITL). After discontinuation of methotrexate and follow-up, no lymph node shrinkage was observed, and the patient had strong general malaise, so chemotherapy was started for AITL. After the start of chemotherapy, the patient's general symptoms improved quickly. RS3PE syndrome is a polyarticular, rheumatoid factor-negative, polyarticular synovitis with symmetric dorsolateral hand-palmar symmetric indentation edema that occurs mainly in elderly patients. It is also noted as a paraneoplastic syndrome, with 10%-40% of patients having malignant tumors. When our patient was diagnosed with RS3PE syndrome, a search for malignancy was performed, but there were no findings suggestive of malignant disease. However, after methotrexate and tacrolimus administration was started, the patient developed rapid lymph node enlargement, and the pathology showed AITL. The possibility of AITL as an underlying disease and RS3PE syndrome as a paraneoplastic syndrome, or conversely, OI-LPD/AITL associated with immunosuppressive therapy for RS3PE syndrome is considered. We herein report this case, as sufficient recognition is required for a proper diagnosis to be made and treatment of RS3PE syndrome to be performed.


Assuntos
Linfadenopatia Imunoblástica , Linfoma de Células T , Síndromes Paraneoplásicas , Masculino , Humanos , Idoso , Metotrexato , Fator Reumatoide , Tacrolimo/uso terapêutico , Linfadenopatia Imunoblástica/complicações , Linfadenopatia Imunoblástica/tratamento farmacológico , Linfadenopatia Imunoblástica/patologia , Síndromes Paraneoplásicas/complicações , Síndromes Paraneoplásicas/diagnóstico , Edema/complicações , Edema/diagnóstico , Linfoma de Células T/complicações , Linfoma de Células T/tratamento farmacológico , Terapia de Imunossupressão
2.
Rinsho Ketsueki ; 63(4): 265-270, 2022.
Artigo em Japonês | MEDLINE | ID: mdl-35491215

RESUMO

A 73-year-old woman was hospitalized with sudden chest pain and hematemesis. Chest computed tomography and upper gastrointestinal endoscopy revealed an idiopathic submucosal hematoma from the cervical esophagus to the esophagogastric mucosal junction. Idiopathic esophageal submucosal hematoma is often prone to a bleeding tendency of an underlying disorder. The patient had a history of essential thrombocythemia (ET) and was taking aspirin. She successfully recovered after aspirin discontinuation and conservative treatment; however, died of cardiopulmonary arrest in the ward on day 9 of hospitalization. The autopsy revealed that the cause of death was pulmonary thromboembolism. This is the first report of ET with submucosal hematoma of the esophagus. The possibility of an esophageal submucosal hematoma should be considered when patients with ET complain of chest pain since ET and treatment with aspirin are considered risk factors for bleeding. Additionally, close attention should be focused on the risk of developing thrombosis if a patient with myeloproliferative neoplasm is required to discontinue antithrombotic therapy due to a bleeding event.


Assuntos
Doenças do Esôfago , Trombocitemia Essencial , Idoso , Aspirina/efeitos adversos , Dor no Peito/complicações , Doenças do Esôfago/etiologia , Doenças do Esôfago/terapia , Feminino , Fibrinolíticos/efeitos adversos , Hemorragia Gastrointestinal/induzido quimicamente , Hemorragia Gastrointestinal/complicações , Hematoma/induzido quimicamente , Hematoma/complicações , Humanos , Trombocitemia Essencial/complicações , Trombocitemia Essencial/tratamento farmacológico
3.
Nihon Ronen Igakkai Zasshi ; 59(1): 90-95, 2022.
Artigo em Japonês | MEDLINE | ID: mdl-35264539

RESUMO

AIM: Acquired hemophilia A (AHA) is an acquired autoantibody (inhibitor) against blood coagulation factor VIII (FVIII) that significantly reduces FVIII activity and causes a bleeding tendency. Immune acquired coagulation factor deficiency. The peak age of onset is in the 70s. In Japan, which has an aging society, the number of reports has recently been increasing, and it should be noted that AHA is a bleeding disease that can occur in the elderly. Examined 5 cases of AHA that were experienced in our hospital. The FVIII inhibitor level, APTT, underlying disease, treatment history, and outcome were retrospectively examined using medical records. RESULTS: The age of onset was 76-93 years. At the time of diagnosis, the Hb (mg/dL) value was 6.1-10.3, the APTT was 75.6-203.2 seconds, the FVIII inhibitor value (BU/mL) was 18-686, and the platelet count was within the normal range in all cases. Bleeding control was possible using a bypass hemostatic agent in 4 patients. All patients underwent immunosuppressive therapy. Two patients were discharged alive and 3 patients died. The cause of death was infectious disease in all cases. The total prednisolone-equivalent dose of the deceased patients was 1,240-3,206 mg; one patient was treated with cyclophosphamide and was treated with dexamethasone. CONCLUSION: Long-term immunosuppressive therapy is expected to increase the risk of infection in elderly patients. The risk assessment of AHA treatment-related bloodstream infections is insufficient, and it will be necessary to accumulate data and consider appropriate assessments and countermeasures.


Assuntos
Hemofilia A , Sepse , Idoso , Idoso de 80 Anos ou mais , Fator VIII/uso terapêutico , Hemofilia A/tratamento farmacológico , Humanos , Terapia de Imunossupressão , Estudos Retrospectivos , Sepse/complicações
4.
Gan To Kagaku Ryoho ; 49(13): 1473-1475, 2022 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-36733106

RESUMO

Monomorphic epitheliotropic intestinal T-cell lymphoma(MEITL)is classified under type Ⅱ enteropathy-associated T-cell lymphoma(EATL). It is a rare disease with a low incidence rate. This study reports a case of a patient with MEITL who developed small intestinal perforation during chemotherapy. The patient was a 55-year-old woman who presented to a previous clinic with epigastric pain. Enteroscopy results showed a map-like ulcer in the jejunum. Examination of the tissue specimen collected from this site suggested T-cell lymphoma. The patient was referred to our hospital for chemotherapy. Seven days following the initiation of chemotherapy, an abdominal computed tomography(CT)revealed free air, leading to a diagnosis of gastrointestinal perforation. Emergency surgery was performed. Intraoperatively, bowel perforation and a degenerative ulcer were observed at 95 cm and 80 to 115 cm from the Treitz' ligament, respectively. In addition, all-layer intestinal necrosis was noted 150 and 90 cm from the terminal ileum. Total resection and anastomosis were performed. Postoperatively, the patient developed sepsis due to chemotherapy-related pancytopenia but recovered. She was discharged on postoperative day 24. Subsequently, positron emission tomography(PET)-CT revealed residual intestinal tumor cells and peritoneal dissemination. Chemotherapy was initiated, but there was no response. The patient died after 6.5 months. A radical treatment for MEITL has not yet been established. More case reports are needed to improve the prognosis of this disease.


Assuntos
Linfoma de Células T Associado a Enteropatia , Neoplasias Intestinais , Perfuração Intestinal , Linfoma de Células T , Feminino , Humanos , Pessoa de Meia-Idade , Linfoma de Células T Associado a Enteropatia/complicações , Linfoma de Células T Associado a Enteropatia/diagnóstico , Linfoma de Células T Associado a Enteropatia/patologia , Perfuração Intestinal/induzido quimicamente , Perfuração Intestinal/cirurgia , Úlcera/induzido quimicamente , Úlcera/cirurgia , Linfoma de Células T/tratamento farmacológico , Linfoma de Células T/cirurgia , Linfoma de Células T/complicações , Neoplasias Intestinais/tratamento farmacológico , Neoplasias Intestinais/cirurgia , Neoplasias Intestinais/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...